Recently, a team led by Chief Physician Chen Yicheng from the Department of Urology at Sir Run Run Shaw Hospital of Zhejiang University, together with a multidisciplinary team (MDT) including Nuclear Medicine, Medical Oncology, and Radiology, successfully administered Lutetium-177 Tixivapitide Injection (radioligand therapy) to a 70-something patient with prostate cancer.

With the continuous development of technologies such as artificial intelligence, multi-modal image fusion, and real-time dose monitoring, the CyberKnife of the future will have a higher level of intelligence. Its faster image processing speed, more accurate motion prediction models, and more adaptive treatment plan adjustments will allow this "radiation therapy drone" to cope freely on the anti-cancer battlefield, bringing patients safer, more efficient, and non-invasive new

As a common high-incidence cancer unique to men, prostate cancer often develops silently to an advanced stage without obvious symptoms. When many prostate cancer patients seek medical treatment, they not only focus on the treatment method itself but also worry about whether the treatment process and subsequent recovery will bring inconvenience and embarrassment to their lives and work. So, is there a non-invasive way to effectively treat prostate cancer?